Testosterone replacement therapy in Klinefelter syndrome - follow-up study associating hemostasis and RNA expression
CONCLUSIONS: KS is associated with a specific expression profile contributing to fibrinolytic impairment and increased thrombotic risk in the patients. TRT in KS has potential for alleviating the prothrombotic phenotype, in particular by reducing body fat and fibrinogen.CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT02526628, Registered August 18, 2015.PMID:37962976 | DOI:10.1210/clinem/dgad658
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Simon Chang Jesper Just Anne Skakkeb æk Emma B Johannsen Jens Fedder Claus H Gravholt Anna-Marie B M ünster Source Type: research
More News: Clinical Trials | Endocrinology | Genetics | Klinefelter's Syndrome | Low Testosterone | Study | Thrombosis